COM701 is currently being evaluated in a Phase 1 study in patients with advanced solid tumors. The study is designed to evaluate the safety and tolerability of COM701 as monotherapy and in combination with a PD-1 inhibitor. Additional endpoints include evaluation of PK/PD and preliminary clinical activity in certain tumor types such as non-small cell lung, breast, ovarian and endometrial cancer. Preclinical data demonstrate that these tumor types express a high level of the biomarkers PVRIG and PVRL2.
The Phase 1 study is ongoing in multiple medical centers the United States across two arms of the study: Arm A (monotherapy dose escalation) and Arm B (combination dose escalation). Additional Information on the COM701 Phase 1 clinical trial can be found here.
Preliminary results from the monotherapy dose escalation study were presented at SITC 2019 and AACR 2020. These data demonstrated that COM701 is well-tolerated and shows encouraging signals of anti-tumor activity as a monotherapy and in combination with Opdivo® in a highly refractory, all-comer patient population.
COM902 is currently being evaluated in a Phase 1 study in patients with advanced malignancies. The study is designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of escalating doses of COM902 monotherapy.
The Phase 1 study is currently enrolling at leading centers in the United States and is expected to include approximately 45 patients. Additional Information on the COM902 Phase 1 clinical trial can be found here.